How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?
MDM Policy and Practice - United States
doi 10.1177/2381468319892237
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2019
Authors
Publisher
SAGE Publications